Author: biocytogen

American Society for Cell Biology 2022

November 29, 2022

Join us at booth #704 at Cell Bio 2022 from December 3-7 in Washington, DC, hosted by American Society for Cell Biology (ASCB)! Whether you need humanized models, PK/PD services, or antibody discovery services, we’d love to partner with you to evaluate your novel immunotherapies. We have extensive experience testing novel monoclonal antibodies, bispecific antibodies, and […]

Read More

Biocytogen Enters into Antibody Agreement with ADC Therapeutics

November 28, 2022

BEIJING, China, November 28, 2022 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announced that it has entered into an evaluation and option agreement with ADC Therapeutics SA. Biocytogen will grant ADC Therapeutics a license to evaluate Biocytogen’s proprietary antibodies against three tumor targets, with an option to license selected antibodies at a […]

Read More

Antibody Engineering & Therapeutics 2022

November 22, 2022

Join us at booth #608 at Antibody Engineering & Therapeutics 2022 in San Diego, CA, December 4 – 8! Learn more about our antibody discovery capabilities and humanized antibody mice. Our Beacon- and FACS-based screening services can identify hundreds, or even thousands, of single B cells that generate antibodies to your target in one day, […]

Read More

First Patient Dosed in Phase 1/2 Trial Evaluating YH001 in Combination with Envafolimab and Doxorubicin in Front Line Sarcoma Patients

November 21, 2022

Beijing, China and San Diego, CA, November 21, 2022 – Eucure (Beijing) Biopharma Co., Ltd. (“Eucure Biopharma”), a wholly owned subsidiary of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) and TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), today jointly announced dosing of the first patient in a Phase 1/2 Trial that studies its CTLA-4 antibody YH001 in combination […]

Read More

Selecting the Right Platform for Your Antibody Discovery Project

November 17, 2022

Contributed by John Charpentier, Ph.D. and Li Hui, M.D., Ph.D. The variety of technology platforms available for therapeutic antibody discovery can be both exciting and daunting. Here we provide some general guidelines to help investigators understand their capabilities and applications. Since the introduction of hybridoma technology in the 1970s, numerous antibody discovery platforms have been […]

Read More

BioMice’s Target Humanized Mouse Models Enable Preclinical Toxicity Studies to Support IND Approval

November 10, 2022

In February 2022, to meet the challenge of NHP shortage, the Food and Drug Administration (FDA) published a new guideline – Nonclinical Considerations for Mitigating Nonhuman Primate Supply Constraints Arising from the COVID-19 Pandemic: Guidance for Industry. To quote, “although the stated preference of ICH S6(R1)8 is for testing the clinical candidate (in the NHP), […]

Read More

Neuroscience 2022

November 8, 2022

Join us at booth #2703 at Neuroscience 2022 in San Diego, CA, November 12-16! Learn more about our latest model and service offerings. Whether you need humanized or custom models, pharmacology services, or antibody discovery assistance, we’d love to partner with you! Each year, scientists from around the world congregate to discover new ideas, share […]

Read More

Biocytogen to Deliver 1 Oral and 3 Poster Presentations at PEGS EUROPE 2022, Introducing RenLite Platform, TCR-mimic Platform, and Antibody Assets

November 8, 2022

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) announced today that the company will present at the upcoming Protein & Antibody Engineering Summit (PEGS EUROPE) conference in Barcelona, Spain on November 14-16, 2022. Frank An, Ph.D., Senior Director of Antibody Therapeutics at Biocytogen, will give an oral presentation at 13:50-14:20 on Tuesday, November 15, introducing […]

Read More

37th SITC Annual Meeting 2022

November 3, 2022

Join us at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Boston, MA! Our booth will be open to greet visitors on November 10th and 11th at the Boston Exhibition and Convention Center! Stop by to chat with us (booth #743) to check out our latest model and service offerings. Whether you […]

Read More

Biocytogen to Present Progress of Antibody Assets and Five Fully Human Antibody Discovery Platforms at ChinaBio 2022

November 3, 2022

Biocytogen’s BD & Licensing team will attend and present at the upcoming ChinaBio virtual conference on November 8-11, 2022. The company will give an oral presentation with the title of “Introduction of Biocytogen’s pipeline assets, innovative fully human antibody RenMice platform and Project Integrum for antibody discovery against 1000+ potential targets”. The talk will introduce […]

Read More

Back to top